Novel radiopharmaceuticals for bladder cancer evaluation

Key Points

• Evaluate the effectiveness of novel radiopharmaceuticals for bladder cancer assessment and their potential for clinical use.
• Analysis of new PET agents alongside standard reference agent [18F]FDG.
• Assessment of staging and therapy monitoring efficacy in bladder cancer.
• Recommendation for multicentric validation and standardized imaging protocols.
• Novel radiopharmaceuticals show encouraging results compared to standard agents.
• Potential for improved staging accuracy and monitoring of treatments.
• Need for further validation in broader clinical settings.